Treating alopecia androgenetica with limited options, such as spironolacton, dutasteride, finasteride, minoxidil 5%, Rogaine foam for men, a shampoo with ketoconazol, iron supplement and dermarolling.
A user shared their positive experience with a hair transplant in Turkey using the DHI and Sapphire FUE techniques, without taking finasteride or minoxidil post-surgery. They emphasized that transplanted hairs from the donor area are resistant to hair loss, but acknowledged that native hairs might still thin without medication.
A user's extreme regimen for hair loss, which includes taking oral and topical medications such as minoxidil, dutasteride, cyproterone acetate and bicalutamide, but still experiencing miniaturization. Suggestions were made to try other treatments such as RU58841 and Pyrilutamide, while also considering mental health treatment and advice on lookmaxxing.
The user shared their 4-month hair loss progress, noting initial hair loss followed by improvement. They used a dermaroller twice a week with varying needle sizes.
The user experienced hair shedding with finasteride and found minoxidil helpful for regrowth but insufficient alone. They are considering dutasteride but are concerned about potential shedding similar to their experience with finasteride.
A user shared their 11-year journey with alopecia, using finasteride, dutasteride, and a hair transplant. They encouraged others not to panic, noting that hair miniaturization can take over 15 years to complete.
A user experienced hairline improvement after four weeks on 1.5mg dutasteride but had side effects like reduced libido and sensitive nipples. They plan to switch to finasteride to manage these side effects.
A user is seeking a brush for dry, thick hair that can effectively stimulate the scalp and distribute natural oils. Another user recommends a "wet" brand detangling brush that works well for their coarse, dry hair and helps distribute argan oil to the scalp.
A user experienced hair thinning after using Adapalene gel 1% for skin care, suspecting it contributed to hair loss alongside depression and anxiety. They stopped using Adapalene and switched to a Minoxidil/Finasteride formula, noticing hair improvement, while others in the conversation doubted Adapalene's impact on hair loss.
A 25-year-old woman with androgenic alopecia is experiencing hair dryness and damage after using topical minoxidil and Nizoral. She is advised to reduce washing frequency, use a bond builder like K18, apply a silicone-based serum, and consider using a shower filter and different oils like argan oil for better hair health.
The user shared a 6-month update on their hair transplant progress, noting they still use oral minoxidil and dutasteride daily. They are pleased with the results but observe increased hair shedding during showers.
A user shared their positive experience using dutasteride 0.5 mg and minoxidil 5% for hair loss, noting significant improvement in 3 months without side effects. They used Avodart for dutasteride and Costco's minoxidil, taking dutasteride pills every other day and applying topical minoxidil.
The conversation discusses difficulty in distinguishing between new hair growth and thinning hair at the temples after using microneedling and a rosemary peppermint topical for four weeks. The advice given is to wait a few months to see if the hairs grow out to determine their nature.
A user added sandalore to minoxidil for hair loss, observing some vellus hair growth and less scalp inflammation. Others tried sandalore with mixed results, discussing dosage and effectiveness compared to minoxidil and finasteride.
The post discusses a phase 2 trial for HMI-115, a hair loss treatment, in China, specifically seeking volunteers aged 18-65 with Norwood 3 vertex, 4, and 5 hair loss. The conversation includes questions about the specific recruitment criteria and how to volunteer.
The user experienced tiny vellus hairs from 0.5mg finasteride and 2.5mg minoxidil over 9 months. Topical minoxidil, alfatradiol, and RU58841 applied twice daily for 1.5 months significantly improved temple hair regrowth.
Evidence-based treatments for androgenic alopecia, such as minoxidil, finasteride, low-level laser light therapy, dutasteride, platelet-rich plasma, and topical ketoconazole. It discusses the efficacy, safety, and mechanism of action of these treatments, as well as future developments in understanding this polygenic condition.
The user is considering using Tacrolimus Solution and topical Dutasteride to avoid shedding caused by Minoxidil, which they fear may lead to facial side effects. They are also concerned about scalp sensitivity and are exploring different treatment bases to manage seborrheic dermatitis.
The conversation provides tips to reduce facial skin side effects from Minoxidil, such as changing pillowcases, sleeping on the back, careful application, hydration, and taking breaks. One reply suggests that alcohol in Minoxidil formulations, not Minoxidil itself, may cause skin aging.
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
A user shared their positive experience using Fleava (copper peptides), minoxidil, and micro needling for hair regrowth, noting significant improvement in their hairline. Other users believe the success is primarily due to micro needling and minoxidil.
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.
The conversation is about a user's impressive hair recovery over 14 months using 0.5mg dutasteride, 5% topical minoxidil, saw palmetto shampoo, and occasional microneedling. The results are highly praised by others, with many expressing admiration and hope for similar outcomes.
Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.
The conversation discusses severe hair shedding and thinning, with the original poster using finasteride, oral minoxidil, and other supplements without improvement. The discussion highlights the possibility of telogen effluvium and the importance of addressing potential underlying health issues, such as stress and gut health, rather than assuming diffuse unpatterned alopecia (DUPA).
Users discussed their experiences with oral minoxidil and dutasteride for hair loss. Most reported positive results, including hair regrowth and improved hair quality, with minimal side effects.
A peptide from Japanese water chestnut fruit may help with hair loss by suppressing DHT's effect on hair follicle cell death, potentially serving as a finasteride alternative. The treatment's effectiveness and safety in humans remain uncertain.